Global Blood Therapeutics (NASDAQ: GBT) and Caladrius Biosciences (NASDAQ:CLBS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Insider and Institutional Ownership

86.1% of Global Blood Therapeutics shares are held by institutional investors. Comparatively, 6.5% of Caladrius Biosciences shares are held by institutional investors. 5.3% of Global Blood Therapeutics shares are held by company insiders. Comparatively, 13.1% of Caladrius Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Global Blood Therapeutics has a beta of 4.21, meaning that its share price is 321% more volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Profitability

This table compares Global Blood Therapeutics and Caladrius Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Global Blood Therapeutics N/A -38.92% -36.49%
Caladrius Biosciences -84.10% -180.68% -51.96%

Analyst Ratings

This is a summary of current ratings and recommmendations for Global Blood Therapeutics and Caladrius Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Global Blood Therapeutics 0 0 11 0 3.00
Caladrius Biosciences 0 0 2 0 3.00

Global Blood Therapeutics currently has a consensus price target of $55.70, indicating a potential upside of 72.45%. Caladrius Biosciences has a consensus price target of $6.75, indicating a potential upside of 91.22%. Given Caladrius Biosciences’ higher probable upside, analysts clearly believe Caladrius Biosciences is more favorable than Global Blood Therapeutics.

Valuation and Earnings

This table compares Global Blood Therapeutics and Caladrius Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Global Blood Therapeutics N/A N/A -$95.43 million ($2.47) -13.08
Caladrius Biosciences N/A N/A N/A $1.40 2.52

Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Caladrius Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Global Blood Therapeutics beats Caladrius Biosciences on 6 of the 9 factors compared between the two stocks.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company’s GBT440 is an investigational drug that increases hemoglobin’s affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.